Agilex has extensive experience developing and validating like-binding assays for specific immune-oncology therapeutics. From a...
Come to Our EBF Session in Barcelona to Hear how Agilex Can Make Your PK Data SPARCL SPARCL stands for Spatial Proximity Analyt...
How do Australia's streamlined regulatory process and global tax incentive apply to your toxicology studies? There are many ben...
As Agilex Biolabs continues its global expansion and corporate evolution as part of the Healius network, Stephen McIntyre has been selected to take the position of Chief Executive Officer.
by Holly Stefl, Chief Commercial Officer It is with much enthusiasm that Agilex Biolabs introduces its newest Senior Developmen...
by Kurt Sales In the realm of bioanalytical research, immunoassays stand as a cornerstone technology, enabling the precise dete...
by Holly Stefl, Chief Commercial Officer Agilex Biolabs is proud to introduce the West Coast of the United States to their new...
by Dr. Kurt Sales, Chief Scientific Officer Pharmacokinetics is a key component in a drug development program in enabling us to...
by Dr. Kurt Sales, Chief Scientific Officer In the ever-evolving landscape of pharmaceuticals, advancements in science have led...
Dr. Kurt Sales Presents Groundbreaking Findings at WRIB Conference Recently Dr. Kurt Sales, the Chief Scientific Officer of Agi...
by Kurt Sales The rise of Cell and Gene Therapy products is increasingly becoming more prevalent. At Agilex we are seeing more...
Agilex Biolabs, the leading bioanalytical laboratory supporting Australian clinical trials, has established its first satellite processing unit staffed with highly specialised technicians on the fifth floor of the CMAX Clinical Research facility in Adelaide, SA.
Recent Report Shows Australia Rising to 3rd in Number of Industry-Initiated Phase I Clinical Trials in 2021 The Association of...
As Agilex Biolabs continues its global expansion and corporate evolution as part of the Healius network, Stephen McIntyre has been selected to take the position of Chief Executive Officer.
Rescue studies are a particular point of strength at Agilex Biolabs, where the bioanalytical experts are driven to solve challenges presented by what we call “the weird and wonderful”.
On November 21, 2022, Agilex Biolabs was named this year’s winner for the Editor’s Choice Award for “Top company in clinical research-based development” in BioSpectrum Asia Excellence Awards.
Agilex Biolabs, the leading bioanalytical laboratory supporting Australian clinical trials, has established its first satellite processing unit staffed with highly specialised technicians on the fifth floor of the CMAX Clinical Research facility in Adelaide, SA.
Agilex Biolabs has expanded its capacity to better serve the biotech, pharmaceutical and animal health industry with the opening of its new in-vivo testing facility.
Circulating tumor DNA (ctDNA) is tumor-deriver fragmented DNA which originates either directly from the tumor or from circulating tumor cells.
Immunogenicity assessment of biotherapeutics is a regulatory requirement and key parameter for assessing the safety and efficacy of a drug candidate.
Immunogenicity assessment is a critical safety attribute for biotherapeutics undergoing clinical development.
Dr. Kurt Sales Appointed as Chief Scientific Officer at Agilex Biolabs Kurt Sales as Chief Scientific Officer will lead future...
Learn how to improve Bioanalytical clinical outcomes by performing MetID characterisation. Leading experts Heather Heading and...
Large Molecule Facility Doubles Size of Australia’s Top Bioanalytical Laboratory Agilex Biolabs has launched its new laborato...
